Last reviewed · How we verify
NCT05430503: Long_COVID_Ex
Long COVID and Post-exertional Pulmonary Diffusion
trial testing Lung volumes, spirometry and standard single-breath DLCO were measured at rest while combined DLNO and DLCO were measured at rest and post-exercise in Long COVID in 32 participants. Completed in 15 June 2022.
15 June 2022
Quick facts
| Lead sponsor | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 32 |
| Start date | 24 May 2022 |
| Primary completion | 15 June 2022 |
| Estimated completion | 15 June 2022 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Lung volumes, spirometry and standard single-breath DLCO were measured at rest while combined DLNO and DLCO were measured at rest and post-exercise
Conditions studied
- Long COVID — all drugs for Long COVID →
- Breathlessness — all drugs for Breathlessness →
- Exercise Intolerance — all drugs for Exercise Intolerance →
- Alveolar Lung Disease — all drugs for Alveolar Lung Disease →
Sponsor
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy — full company profile →
Who can join
Eligibility, any sex, with Long COVID or Breathlessness. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Aim of investigators was to study whether abnormalities of lung diffusing capacity for nitric oxide (DLNO) and carbon monoxide (DLCO) in long COVID may have a clinical impact in relation to exercise intolerance.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Nitric Oxide Signaling and Sensing in Age-Related Diseases.
Mazuryk O, Gurgul I, Oszajca M, Polaczek J, et al · · 2024 · cited 14× · PMID 39456466 · DOI 10.3390/antiox13101213 -
Lung diffusing capacities for nitric oxide and carbon monoxide at rest and post-walking in long COVID.
Barisione G, Brusasco V. · · 2023 · cited 8× · PMID 37070120 · DOI 10.1183/23120541.00363-2022
Verify or expand the search:
- PubMed search for NCT05430503
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Long COVID
Currently open trials in the same condition.
- NCT05931497 — Sauna for Long Covid · NA · recruiting
- NCT06452095 — Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine Trial - Effect of Hyperbaric Oxygen Therapy fo · NA · recruiting
- NCT07316127 — Immunoadsorption in Autoimmune Long COVID · Phase 2 · recruiting
- NCT07435805 — Long-Term Health Effects of Previous COVID-19 in Patients Undergoing Preoperative Anesthesia Evaluation · recruiting
- NCT07278206 — Brain Stimulation in Long COVID · NA · recruiting
Other IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy trials
Trials by the same sponsor.
- NCT07091838 — Lung Diffusing Capacities Normality Thresholds in Pulmonary Fibrosis and Emphysema · completed
- NCT05998837 — GLUcose Transport and REnalPROtection in Chronic Kidney Disease · Phase 2, PHASE3 · completed
- NCT04610554 — Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide Early After Mild-to-severe COVID-19 · completed
- NCT03601520 — Mechanisms of Pulmonary Diffusion Limitation in Systemic Sclerosis · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05430503 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
- Last refreshed: 24 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05430503.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing